// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























999 Abstracts

Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).

Stuthi Perimbeti - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Therapeutic potential of plant-derived nanovesicles for neuroendocrine prostate cancer.

Sharanjot Saini - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Transdermal square-wave testosterone therapy: A pilot trial in metastatic castration-resistant prostate cancer.

Nellowe Candelario - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting.

Kelly Lehner - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Solid malignancies

Enzalutamide

Using microfluidic models to evaluate whether monocyte preconditioning plays a role in tumor-associated macrophage mediated resistance to hormone therapy in men with prostate cancer.

David Kosoff - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Enzalutamide

Biology and usefulness of [-2]proPSA as a prognostic marker in CRPC patients.

Yoshiyuki Miyazawa - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Enzalutamide

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Amy K Taylor - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Enzalutamide

Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in BRCA2.

Minqi Huang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Ahmed Zedan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.

Sachdev P. Thomas - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.

Manish Kohli - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Enzalutamide

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

Daniel J. George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.

Shunsuke Kamijo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.

Elaine T. Lam - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Enzalutamide

Immune activation and clinical response from enzalutamide (enza) alone or with radium223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC)

Peter Zang - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Overcoming resistance to NK-mediated lysis in enzalutamide-resistant prostate cancer cells

Madeline Dahut - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Copyright © 2026. QuantiNova All rights reserved